Vaxcyte teams up with Thermo Fisher to ensure future vaccine production
Source: SeekingAlpha
2025-09-30 09:03:48 ET
More on Vaxcyte, Thermo Fisher Scientific
- Thermo Fisher: A Wide-Moat Leader With Multi-Year Growth Ahead
- Thermo Fisher: A Hold For Stability, Not For Outperformance
- Vaxcyte, Inc. (PCVX) Presents At Cantor Global Healthcare Conference 2025 Transcript
- Glenview Capital's Q2 moves include new stakes in Dick's Sporting, Disney exit
- Vaxcyte GAAP EPS of -$1.22 misses by $0.04
Read the full article on Seeking Alpha
For further details see:
Vaxcyte teams up with Thermo Fisher to ensure future vaccine production
Vaxcyte Inc.
NASDAQ: PCVX
PCVX Trading
-4.98% G/L:
$56.52 Last:
259,831 Volume:
$58.62 Open:
PCVX Latest News
February 24, 2026 04:05:00 pm
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 11, 2026 04:05:00 pm
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
February 10, 2026 04:05:00 pm
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
PCVX Stock Data
$7,801,730,421
136,657,209
0.01%
97
N/A
Biotechnology & Life Sciences
Healthcare
US
San Carlos
